Eli Lilly and Company (NYSE: LLY) announced that the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted to recommend approval of its osteoporosis drug EVISTA(R) (raloxifene HCl) for a new use to reduce invasive breast cancer risk in two populations: postmenopausal women with osteoporosis and postmenopausal women at high risk for breast cancer.
According to a new study published online today in the Journal of the National Cancer Institute, prostate cancer patients treated by highly experienced surgeons are much more likely to be cancer-free five years after surgery than patients treated by surgeons with less experience.
The medical community has been debating for many years whether, and to what extent, postmenopausal hormone therapy (HT) use is associated with a higher risk of breast cancer, says Professor Amos Pines, President of the International Menopause Society.
The Cancer Therapy & Research Center Institute for Drug Development, in collaboration with Oncolytics Biotech Inc., a biotechnology company, has enrolled the first two patients in a new Phase II clinical study for patients with various types of sarcomas that have metastasized to the lung.
Newer drug therapies available since the 1990s, in particular aromatase inhibitors, improve the survival of women with metastatic breast cancer in the general population, according to a new study.
A follow up to a previous study on group therapy in breast cancer patients finds group therapy does not prolong the lives of women with metastatic breast cancer.
A protein whose function is lost in a broad array of cancers normally suppresses the spread of prostate cancer, MIT researchers and colleagues have shown. As a result, testing for loss of the protein, called Protein 4.1B, could help clinicians predict which cancers are likely to spread, or metastasize.
University of Florida researchers have successfully used molecular probes to detect subtle differences in leukemia cells from patient samples, an achievement that could lead to more effective ways to diagnose and treat cancer.
According to a new study in Value in Health, women coping with the strain of being mistakenly diagnosed with breast cancer have not been adequately studied in the past.
Men and their physicians need not hesitate to use a drug proven effective in preventing prostate cancer out of concern that it is likely to cause sexual dysfunction, say authors of a study conducted by the Southwest Oncology Group.